A Minority Subpopulation of CD133⁺/EGFRvIII⁺/EGFR^― Cells Acquires Stemness and Contributes to Gefitinib ResistanceLIU, Xu-Jie; WU, Wen-Tao; SHUO HAN et al.CNS neuroscience & therapeutics (Print). 2013, Vol 19, Num 7, pp 494-502, issn 1755-5930, 9 p.Article

Distinctive activation patterns in constitutively active and gefitinib-sensitive EGFR mutantsCHEN, Y.-R; FU, Y.-N; LIN, C.-H et al.Oncogene (Basingstoke). 2006, Vol 25, Num 8, pp 1205-1215, issn 0950-9232, 11 p.Article

Development of the novel biologically targeted anticancer agent gefitinib: Determining the optimum dose for clinical efficacyWOLF, Michael; SWAISLAND, Helen; AVERBUCH, Steven et al.Clinical cancer research. 2004, Vol 10, Num 14, pp 4607-4613, issn 1078-0432, 7 p.Article

Gefitinib-Induced Paronychia: Response to Autologous Platelet-Rich PlasmaKWON, Soon-Hyo; CHOI, Jae-Woo; HONG, Jong-Soo et al.Archives of dermatology (1960). 2012, Vol 148, Num 12, pp 1399-1402, issn 0003-987X, 4 p.Article

Contact spotting of protein microarrays coupled with spike-in of normalizer protein permits time-resolved analysis of ERBB receptor signalingLÖBKE, Christian; LAIBLE, Mark; RAPPL, Claudia et al.Proteomics (Weinheim. Print). 2008, Vol 8, Num 8, pp 1586-1594, issn 1615-9853, 9 p.Article

Drug localization in different lung cancer phenotypes by MALDI mass spectrometry imaging : Mass Spectrometry - One of the pillars of ProteomicsMARKO-VARGA, György; FEHNIGER, Thomas E; REZELI, Melinda et al.Journal of proteomics (Print). 2011, Vol 74, Num 7, pp 982-992, issn 1874-3919, 11 p.Article

In Silico Identification of Significant Detrimental Missense Mutations of EGFR and Their Effect with 4-Anilinoquinazoline-Based DrugsRAJASEKARAN, R; SETHUMADHAVAN, Rao.Applied biochemistry and biotechnology. 2010, Vol 160, Num 6, pp 1723-1733, issn 0273-2289, 11 p.Article

Gefitinib-induced epidermal growth factor receptor-independent keratinocyte apoptosis is mediated by the JNK activation pathwayLU, P.-H; KUO, T.-C; CHANG, K.-C et al.British journal of dermatology (1951). 2011, Vol 164, Num 1, pp 38-46, issn 0007-0963, 9 p.Article

Antitumor activity of gefitinib in Malignant rhabdoid tumor cells in vitro and in vivoKUWAHARA, Yasumichi; HOSOI, Hajime; OSONE, Shinya et al.Clinical cancer research. 2004, Vol 10, Num 17, pp 5940-5948, issn 1078-0432, 9 p.Article

United States Food and Drug Administration Drug approval summary: Gefitinib (ZD1839; Iressa) tabletsCOHEN, Martin H; WILLIAMS, Grant A; BAIRD, Amy et al.Clinical cancer research. 2004, Vol 10, Num 4, pp 1212-1218, issn 1078-0432, 7 p.Article

Efficacité du gefitinib (Iressa) pour le traitement d'un carcinome bronchioloalvéolaire inopérable = Efficacy of gefitinib (Iressa) in the treatment of an inoperable bronchioloalveolar cell carcinomaBAYLE, S; DESCOURT, R; GOUVA, S et al.Revue des maladies respiratoires. 2004, Vol 21, Num 1, pp 153-157, issn 0761-8425, 5 p.Article

Gefitinib as targeted therapy for mucoepidermoid carcinoma of the lung : Possible significance of CRTC1-MAML2 oncogeneO'NEILL, Iain D.Lung cancer. 2009, Vol 64, Num 1, pp 129-130, issn 0169-5002, 2 p.Article

Distribution and function of EGFR in human tissue and the effect of EGFR tyrosine kinase inhibitionYANO, Seiichi; KONDO, Kaoru; YAMAGUCHI, Motonori et al.Anticancer research. 2003, Vol 23, Num 5A, pp 3639-3650, issn 0250-7005, 12 p.Article

Proteomic analysis identifies differentially expressed proteins after HDAC vorinostat and EGFR inhibitor gefitinib treatments in Hep-2 cancer cellsBIANCHI, Laura; BRUZZESE, Francesca; BINI, Luca et al.Proteomics (Weinheim. Print). 2011, Vol 11, Num 18, pp 3725-3742, issn 1615-9853, 18 p.Article

Cellular targets of gefitinibBREHMER, Dirk; GREFF, Zoltan; WISSING, Josef et al.Cancer research (Baltimore). 2005, Vol 65, Num 2, pp 379-382, issn 0008-5472, 4 p.Article

Case 1. Nephrotic syndrome associated with gefitinib therapyKUMASAKA, Ryuichiro; NAKAMURA, Norio; SHIRATO, Kenichi et al.Journal of clinical oncology. 2004, Vol 22, Num 12, pp 2504-2505, issn 0732-183X, 2 p.Article

Dominant papillary subtype is a significant predictor of the response to Gefitinib in adenocarcinoma of the lungYOUNG HAK KIM; ISHII, Genichiro; GOTO, Koichi et al.Clinical cancer research. 2004, Vol 10, Num 21, pp 7311-7317, issn 1078-0432, 7 p.Article

Duration of prior gefitinib treatment predicts survival potential in patients with lung adenocarcinoma receiving subsequent erlotinibASAMI, Kazuhiro; KAWAHARA, Masaaki; ATAGI, Shinji et al.Lung cancer. 2011, Vol 73, Num 2, pp 211-216, issn 0169-5002, 6 p.Article

N-nitrosamine-4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone induced lung tumorigenesis in A/J miceKISHINO, Daizo; KIURA, Katsuyuki; TAKIGAWA, Nagio et al.Lung cancer. 2009, Vol 65, Num 3, pp 284-289, issn 0169-5002, 6 p.Article

Gefitinib ('Iressa', ZD1839) is active against brain metastases in a 77 year old patientROGGERO, Enrico; GIANCARLA, Busi; ANTONELLA, Palumbo et al.Journal of neuro-oncology. 2005, Vol 71, Num 3, pp 277-280, issn 0167-594X, 4 p.Article

Interstitial lung disease induced by gefitinib and Toll-like receptor ligands is mediated by Fra-1TAKADA, Y; GRESH, L; MATSUO, K et al.Oncogene (Basingstoke). 2011, Vol 30, Num 36, pp 3821-3832, issn 0950-9232, 12 p.Article

Epidermal growth factor receptor tyrosine kinase inhibitorsRANSON, M.British journal of cancer. 2004, Vol 90, Num 12, pp 2250-2255, issn 0007-0920, 6 p.Article

Gefitinib ('Iressa', ZDI839) and new epidermal growth factor receptor inhibitorsBLACKLEDGE, G; AVERBUCH, S.British journal of cancer. 2004, Vol 90, Num 3, pp 566-572, issn 0007-0920, 7 p.Article

Density of Demodex folliculorum in Patients Receiving Epidermal Growth Factor Receptor InhibitorsGERBER, Peter A; KUKOVA, Gabriela; BUHREN, Bettina A et al.Dermatology (Basel). 2011, Vol 222, Num 2, pp 144-147, issn 1018-8665, 4 p.Article

Erlotinib after Gefitinib failure in female never-smoker Asian patients with pulmonary adenocarcinomaSUNG HOON SIM; HAN, Sae-Won; DAE SEOG HEO et al.Lung cancer. 2009, Vol 65, Num 2, pp 204-207, issn 0169-5002, 4 p.Article